Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-04-01-02 Progestogens
| Progesterone Cyclogest® |
|
Formulary
|
Pessaries 200mg, 400mg Used in specialist pre-term birth clinic and for patients with recurring miscarriage following IVF. |
|
| Progesterone (micronised) |
|
Formulary
|
Capsules 100mg |
 LSCMMG: Progesterone (micronised) (Utrogestan) NMR |
|
| Ulipristal Esmya® |
|
Formulary
|
Tablets 5mg In accordance with NICE NG88, ulipristal should only be used for intermittent treatment of moderate to severe symptoms of uterine fibroids before menopause and when surgical procedures (including uterine fibroid embolisation) are not suitable or have failed. |
 MHRA Drug Safety Update Feb 2021: Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury |
|
|
| Dienogest |
|
Formulary
|
Tablets 2mg
Treatment of endometriosis.
Following specialist recommendation, when combined oral contraceptives and progestogen-only oral contraceptives have proved ineffective or are not tolerated by the patient.
Manufacturer advises that, if contraception is required, females of childbearing potential should use non-hormonal contraception during treatment. |
|
LSCMMG: Dienogest NMR |
|
Links
- LSCMMG: Diabetes Guideline for antihyperglycaemic therapy in adults with type 2 diabetes
- LSCMMG: Dienogest NMR
- LSCMMG: Progesterone (micronised) (Utrogestan) NMR
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- MHRA Drug Safety Update Feb 2021: Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury
- NHSE guidance to primary care about unregulated providers who supply hormone medications to children and young people for gender incongruence
- NICE NG126: Ectopic pregnancy and miscarriage: diagnosis and initial management
- NICE NG88: Heavy menstrual bleeding: assessment and management